NCT04104854View on ClinicalTrials.gov

Safety and Efficacy of DCB Therapy for de Novo Lesions Under the Guidance of QFR in CHD Patients (UNIQUE-DCB-I Study )

NANot yet recruitingINTERVENTIONAL

Enrollment

220

Participants

Timeline

Start Date

January 1, 2026

Primary Completion Date

December 1, 2028

Study Completion Date

December 1, 2028

Conditions

Coronary Heart Disease

Interventions

DEVICE

drug coated balloon

Balloon/vessel diameter ratio 0.8-1.0, 8-12 ATM (atmosphere), lasting for \>30 seconds

Trial Locations (1)

210006

Nanjing First Hospital, Nanjing

All Listed Sponsors

lead

Nanjing First Hospital, Nanjing Medical University

OTHER

NCT04104854 - Safety and Efficacy of DCB Therapy for de Novo Lesions Under the Guidance of QFR in CHD Patients (UNIQUE-DCB-I Study ) | Biotech Hunter | Biotech Hunter